Cargando…

Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis

INTRODUCTION: Studies on complement activation have implicated a combination of the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP) in triggering the terminal pathway (TP) for each common autoimmune glomerulonephritis (GN). Evaluating different pathways simultaneously may h...

Descripción completa

Detalles Bibliográficos
Autores principales: Genest, Dominique S., Bonnefoy, Arnaud, Khalili, Myriam, Merlen, Clémence, Genest, Geneviève, Lapeyraque, Anne-Laure, Patey, Natacha, Smail, Nassima, Royal, Virginie, Troyanov, Stéphan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091805/
https://www.ncbi.nlm.nih.gov/pubmed/35571000
http://dx.doi.org/10.1016/j.ekir.2022.02.002
_version_ 1784705009629265920
author Genest, Dominique S.
Bonnefoy, Arnaud
Khalili, Myriam
Merlen, Clémence
Genest, Geneviève
Lapeyraque, Anne-Laure
Patey, Natacha
Smail, Nassima
Royal, Virginie
Troyanov, Stéphan
author_facet Genest, Dominique S.
Bonnefoy, Arnaud
Khalili, Myriam
Merlen, Clémence
Genest, Geneviève
Lapeyraque, Anne-Laure
Patey, Natacha
Smail, Nassima
Royal, Virginie
Troyanov, Stéphan
author_sort Genest, Dominique S.
collection PubMed
description INTRODUCTION: Studies on complement activation have implicated a combination of the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP) in triggering the terminal pathway (TP) for each common autoimmune glomerulonephritis (GN). Evaluating different pathways simultaneously may help identify whether one is preferentially activated and, consequently, which is best to target for each disease. METHODS: We followed 112 patients with focal segmental glomerular sclerosis (FSGS), membranous nephropathy (MN), IgA nephropathy (IgAN), lupus nephritis (LN), and antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) for a median duration of 22 (12–52) months. At the time of greatest clinical activity, we simultaneously evaluated urinary C3a (C3 convertase activity), C5a and sC5b-9 (TP), MASP-1 and MASP-2 (LP), C1q (CP), C4a (CP/LP), and Ba and Bb (AP). We evaluated the relation between activation fragments of the AP and CP/LP with the TP. RESULTS: Urinary complement biomarkers for each pathway were associated with the severity of proteinuria. Fragments of the TP were higher among patients with FSGS and MN compared with patients with IgAN, LN, and AAV. For the AP, urinary Ba level was lower in those with IgAN and LN compared with those with FSGS. For the CP/LP, urinary C4a, MASP-1, and MASP-2 levels were similar between diseases whereas urinary C1q levels were lower in those with LN. For each GN, independent associations existed between the activation markers of the AP and CP/LP with the degree of TP activation, except for the AP in AAV, although perhaps underpowered. CONCLUSION: The AP and CP/LP contribute individually to the TP activation in autoimmune GN, and both seem to be valid potential therapeutic targets.
format Online
Article
Text
id pubmed-9091805
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90918052022-05-12 Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis Genest, Dominique S. Bonnefoy, Arnaud Khalili, Myriam Merlen, Clémence Genest, Geneviève Lapeyraque, Anne-Laure Patey, Natacha Smail, Nassima Royal, Virginie Troyanov, Stéphan Kidney Int Rep Clinical Research INTRODUCTION: Studies on complement activation have implicated a combination of the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP) in triggering the terminal pathway (TP) for each common autoimmune glomerulonephritis (GN). Evaluating different pathways simultaneously may help identify whether one is preferentially activated and, consequently, which is best to target for each disease. METHODS: We followed 112 patients with focal segmental glomerular sclerosis (FSGS), membranous nephropathy (MN), IgA nephropathy (IgAN), lupus nephritis (LN), and antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) for a median duration of 22 (12–52) months. At the time of greatest clinical activity, we simultaneously evaluated urinary C3a (C3 convertase activity), C5a and sC5b-9 (TP), MASP-1 and MASP-2 (LP), C1q (CP), C4a (CP/LP), and Ba and Bb (AP). We evaluated the relation between activation fragments of the AP and CP/LP with the TP. RESULTS: Urinary complement biomarkers for each pathway were associated with the severity of proteinuria. Fragments of the TP were higher among patients with FSGS and MN compared with patients with IgAN, LN, and AAV. For the AP, urinary Ba level was lower in those with IgAN and LN compared with those with FSGS. For the CP/LP, urinary C4a, MASP-1, and MASP-2 levels were similar between diseases whereas urinary C1q levels were lower in those with LN. For each GN, independent associations existed between the activation markers of the AP and CP/LP with the degree of TP activation, except for the AP in AAV, although perhaps underpowered. CONCLUSION: The AP and CP/LP contribute individually to the TP activation in autoimmune GN, and both seem to be valid potential therapeutic targets. Elsevier 2022-02-14 /pmc/articles/PMC9091805/ /pubmed/35571000 http://dx.doi.org/10.1016/j.ekir.2022.02.002 Text en © 2022 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
Genest, Dominique S.
Bonnefoy, Arnaud
Khalili, Myriam
Merlen, Clémence
Genest, Geneviève
Lapeyraque, Anne-Laure
Patey, Natacha
Smail, Nassima
Royal, Virginie
Troyanov, Stéphan
Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis
title Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis
title_full Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis
title_fullStr Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis
title_full_unstemmed Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis
title_short Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis
title_sort comparison of complement pathway activation in autoimmune glomerulonephritis
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091805/
https://www.ncbi.nlm.nih.gov/pubmed/35571000
http://dx.doi.org/10.1016/j.ekir.2022.02.002
work_keys_str_mv AT genestdominiques comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT bonnefoyarnaud comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT khalilimyriam comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT merlenclemence comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT genestgenevieve comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT lapeyraqueannelaure comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT pateynatacha comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT smailnassima comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT royalvirginie comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis
AT troyanovstephan comparisonofcomplementpathwayactivationinautoimmuneglomerulonephritis